196 related articles for article (PubMed ID: 30567691)
1. Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study.
Laing E; Kiss N; Michael M; Gough K; Krishnasamy M
JMIR Res Protoc; 2018 Dec; 7(12):e11228. PubMed ID: 30567691
[TBL] [Abstract][Full Text] [Related]
2. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Laing E; Kiss N; Michael M; Krishnasamy M
Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of malnutrition and nutrition-related complications in patients with gastroenteropancreatic neuroendocrine tumours.
Laing E; Gough K; Krishnasamy M; Michael M; Kiss N
J Neuroendocrinol; 2022 Jun; 34(6):e13116. PubMed ID: 35415851
[TBL] [Abstract][Full Text] [Related]
4. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
5. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention.
Guccione L; Gough K; Drosdowsky A; Fisher K; Price T; Pavlakis N; Khasraw M; Wyld D; Ransom D; Kong G; Rogers M; Leyden S; Leyden J; Michael M; Schofield P
JMIR Res Protoc; 2019 Dec; 8(12):e14361. PubMed ID: 31793892
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
[TBL] [Abstract][Full Text] [Related]
7. Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms.
Kikut J; Jasińska A; Pobłocki J; Brodowski J; Małgorzata S
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32630081
[TBL] [Abstract][Full Text] [Related]
8. Exploring health professional knowledge and management of nutritional complications in neuroendocrine cancer patients: Results of an international multidisciplinary survey.
Laing E; Kiss N; Krishnasamy M; Gough K; Michael M
Clin Nutr ESPEN; 2022 Jun; 49():466-473. PubMed ID: 35623853
[TBL] [Abstract][Full Text] [Related]
9. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.
Kos-Kudła B; Ćwikła J; Ruchała M; Hubalewska-Dydejczyk A; Jarzab B; Krajewska J; Kamiński G
Contemp Oncol (Pozn); 2017; 21(2):115-122. PubMed ID: 28947880
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
Guo LJ; Wang CH; Tang CW
Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
12. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
[TBL] [Abstract][Full Text] [Related]
13. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
Saif MW; Romano A; Smith MH; Patel R; Relias V
Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
[TBL] [Abstract][Full Text] [Related]
14. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
15. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
16. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
17. Nutrition and neuroendocrine tumors: An update of the literature.
Altieri B; Barrea L; Modica R; Muscogiuri G; Savastano S; Colao A; Faggiano A
Rev Endocr Metab Disord; 2018 Jun; 19(2):159-167. PubMed ID: 30267297
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors.
Patel D; Chan D; Cehic G; Pavlakis N; Price TJ
Expert Rev Endocrinol Metab; 2016 Jul; 11(4):311-327. PubMed ID: 30058926
[TBL] [Abstract][Full Text] [Related]
20. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.
; Cho MY; Kim JM; Sohn JH; Kim MJ; Kim KM; Kim WH; Kim H; Kook MC; Park DY; Lee JH; Chang H; Jung ES; Kim HK; Jin SY; Choi JH; Gu MJ; Kim S; Kang MS; Cho CH; Park MI; Kang YK; Kim YW; Yoon SO; Bae HI; Joo M; Moon WS; Kang DY; Chang SJ
Cancer Res Treat; 2012 Sep; 44(3):157-65. PubMed ID: 23091441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
